The US FDA’s oncology committee has approved CT-P10 – Teva’s monoclonal antibody biosimilar to Rituxan (rituximab) for the treatment of various forms of cancer. The development of biosimilars has the potential to increase accessibility to therapies for patients.

https://en.globes.co.il/en/article-teva-receives-fda-nod-for-rituxan-biosimilar-cancer-drug-1001256084